Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Unity Biotechnology, Inc.
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
September 24, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology to Participate in Upcoming Investor Conferences
August 12, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
August 06, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Reports Granting of New Employment Inducement Award
July 24, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
July 22, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
May 14, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
April 25, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
April 23, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
April 15, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
February 06, 2024
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
December 12, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
November 13, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
November 10, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
September 27, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
August 08, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
June 21, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates
May 09, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
April 24, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
April 23, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
March 27, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
March 15, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
February 15, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
February 09, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Reports Granting of New Employment Inducement Award
January 18, 2023
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
November 08, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
November 01, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
October 31, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today
October 19, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
October 11, 2022
From
Unity Biotechnology, Inc.
Via
GlobeNewswire
Tickers
UBX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright